Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 13,133 Shares

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 13,133 shares of the stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $117,409.02. Following the sale, the chief executive officer owned 242,118 shares in the company, valued at $2,164,534.92. The trade was a 5.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, August 18th, Richard Nolan Townsend sold 2,735 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $4.67, for a total transaction of $12,772.45.

Lexeo Therapeutics Trading Up 9.2%

NASDAQ LXEO opened at $9.58 on Friday. The firm’s 50 day simple moving average is $5.91 and its 200 day simple moving average is $4.39. The firm has a market capitalization of $517.32 million, a price-to-earnings ratio of -2.94 and a beta of 1.66. Lexeo Therapeutics, Inc. has a 1 year low of $1.45 and a 1 year high of $11.72.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.04. On average, equities research analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LXEO has been the topic of several research analyst reports. Oppenheimer initiated coverage on Lexeo Therapeutics in a research note on Thursday, July 31st. They issued an “outperform” rating and a $20.00 price objective on the stock. Guggenheim started coverage on shares of Lexeo Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $30.00 price target on the stock. Leerink Partners upped their price objective on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. Finally, Chardan Capital raised their target price on shares of Lexeo Therapeutics from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Lexeo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.86.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. CWM LLC boosted its position in Lexeo Therapeutics by 82.2% during the 3rd quarter. CWM LLC now owns 18,864 shares of the company’s stock worth $125,000 after buying an additional 8,513 shares during the period. Vestal Point Capital LP raised its stake in shares of Lexeo Therapeutics by 184.1% during the second quarter. Vestal Point Capital LP now owns 3,228,161 shares of the company’s stock valued at $12,977,000 after acquiring an additional 2,091,912 shares during the last quarter. Frazier Life Sciences Management L.P. lifted its holdings in shares of Lexeo Therapeutics by 363.1% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company’s stock worth $17,787,000 after purchasing an additional 3,469,210 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Lexeo Therapeutics by 20.4% in the second quarter. BNP Paribas Financial Markets now owns 48,434 shares of the company’s stock worth $195,000 after purchasing an additional 8,223 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its holdings in Lexeo Therapeutics by 39.1% in the second quarter. Bridgeway Capital Management LLC now owns 53,400 shares of the company’s stock valued at $215,000 after purchasing an additional 15,000 shares during the period. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.